SCHEMBL5866548

SCHEMBL5866548

CCc1ccc(C(=O)CCCl)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
ATM Q13315 1/20 0.51
PLK1 P53350 1/20 0.50
RAB9A P51151 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 1/20 0.49
HPGD P15428 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
HSD17B3 P37058 2/20 0.47
MAPT P10636 3/20 0.47
POLB P06746 2/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
THRA P10827 2/20 0.46
THRB P10828 2/20 0.46
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3689140 0.89 ALDH1A1 (0.52) ALDH1A1MEN1KMT2AATMPLK1
SCHEMBL30089549 0.87 ALDH1A1 (0.64) ALDH1A1MEN1KMT2AATMPLK1
SCHEMBL11705123 0.87 HSD17B3 (0.51) ALDH1A1MEN1KMT2AATMPLK1
SCHEMBL6937309 0.85 L3MBTL1 (0.69) ALDH1A1KMT2APLK1RAB9ANPC1
SCHEMBL5270771 0.83 HSD17B3 (0.67) ALDH1A1MEN1KMT2AATMPLK1
SCHEMBL11357034 0.83 THRA (0.62) ALDH1A1MEN1KMT2AATMPLK1
SCHEMBL3234253 0.82 THRA (0.66) ALDH1A1PLK1HPGDL3MBTL1HSD17B3
SCHEMBL10017467 0.82 L3MBTL1 (0.59) ALDH1A1MEN1KMT2AATMPLK1
SCHEMBL14218974 0.82 ALDH1A1 (0.45) ALDH1A1RAB9ASMN1; SMN2NPC1L3MBTL1
SCHEMBL8123386 0.80 HSD17B3 (0.69) ALDH1A1MEN1KMT2AATMPLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109338-B2 For use in the prophylaxis and the treatment of Picornavirus and human rotavirus infections. MARUISHI PHARMACEUTICAL CO., LTD. (JP) 2006-09-19 US disclosed
US-20040009977-A1 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds MARUISHI PHARMACEUTICAL CO., LTD. (JP) 2004-01-15 US disclosed
EP-1380575-A1 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds Maruishi Pharmaceutical Co., Ltd. (JP) 2004-01-14 EP disclosed
US-6541470-B1 Have a potent antiviral activity against picornaviruses and rotaviruses. MARUISHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-01 US disclosed
EP-1081138-A1 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds Maruishi Pharmaceutical Co., Ltd. (JP) 2001-03-07 EP disclosed
US-3979444-A CENTRAL NERVOUS SYSTEM DEPRESSANTS, HYPOTENSIVES THE UPJOHN COMPANY (US) 1976-09-07 US disclosed
US-3965180-A CNS DEPRESSANT THE UPJOHN COMPANY (US) 1976-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009977-A1 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds MAVS, IRF3, EIF2AK2 ALDH1A1 1671/4885MEN1 3221/4885KMT2A 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.